JJDC backed Delix Therapeutics in a $100 million financing for a depression-treatment candidate, extending J&J's work beside Spravato. The planned trials are not expected until the first half of 2027, so the benefit remains a possibility.
This gives J&J a path to work on another possible depression treatment alongside Spravato. The main limit is timing: zalsupindole's Phase 2 trials are expected to start in 2027, and the source reports no trial results yet.
Follow Johnson & Johnson (JNJ) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for JNJ